Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study

We conducted a retrospective cohort study to assess whether treatment with nirmatrelvir/ritonavir was associated with a reduced risk of long COVID. We enrolled 500 adults with confirmed SARS-CoV-2 who were eligible for nirmatrelvir/ritonavir; 250 who took nirmatrelvir/ritonavir and 250 who did not....

Descripción completa

Detalles Bibliográficos
Autores principales: Congdon, Seth, Narrowe, Zev, Yone, Nang, Gunn, Jacob, Deng, Yuting, Nori, Priya, Cowman, Kelsie, Islam, Marjan, Rikin, Sharon, Starrels, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640584/
https://www.ncbi.nlm.nih.gov/pubmed/37951998
http://dx.doi.org/10.1038/s41598-023-46912-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10640584/
https://www.ncbi.nlm.nih.gov/pubmed/37951998
http://dx.doi.org/10.1038/s41598-023-46912-4

Ejemplares similares